North America Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), ByEnd-use, By Country and Growth Forecast, 2024 - 2031

Analysis of Market Size & Trends

The North America Skin Cancer Diagnostics Market would witness market growth of 4.8% CAGR during the forecast period (2024-2031).

The US market dominated the North America Skin Cancer Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $3,355 million by 2031. The Canada market is experiencing a CAGR of 7% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 6.1% during (2024 - 2031).

Technological advancements have profoundly impacted the skin cancer diagnostics market. The accuracy and efficacy of skin cancer detection have been improved by advancements in molecular diagnostics, artificial intelligence (AI), and imaging technologies.

Moreover, dermatoscopy, a non-invasive technique that uses a handheld device to examine skin lesions, has become a standard tool in dermatological practice. Confocal microscopy and high-frequency ultrasound offer detailed imaging at a cellular level, allowing for precise characterization of suspicious lesions.

In North America, the prevalence of skin cancer, particularly melanoma, is consistently increasing. This fuels the demand for accurate and efficient diagnostic tools. The United States has seen a significant rise in skin cancer cases, particularly melanoma, which is one of the most common types of cancer in the country. According to the American Cancer Society, about 100,640 new cases of melanoma are expected to be diagnosed in 2024, with approximately 8,290 deaths expected from the disease Factors contributing to the increased demand for skin cancer diagnostics include higher awareness and screening, increased exposure to ultraviolet (UV) radiation, and indoor tanning practices.

Free Valuable Insights: The Skin Cancer Diagnostics Market is Predict to reach USD 12.8 Billion by 2031, at a CAGR of 5.3%

Based on Type, the market is segmented into Non-Melanoma and Melanoma. Based on Test Type, the market is segmented into Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others. Based on End-use, the market is segmented into Hospital & Clinics, Laboratories, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Castle Biosciences, Inc.
• Bausch Health Companies, Inc. (DermTech, Inc.)
• Canfield Scientific, Inc.
• DermaSensor, Inc.
• F.Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Quest Diagnostics Incorporated.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)
• FotoFinder Systems GmbH
• Veriskin Inc

North America Skin Cancer Diagnostics Market Report Segmentation

By Type

• Non-Melanoma
• Melanoma

By Test Type

• Skin Biopsy
• Imaging Tests
• Dermatoscopy
• Lymph Node Biopsy
• Others

By End-use

• Hospital & Clinics
• Laboratories
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America